pipelin mileston earn in-lin
messag announc full-year financi result guidanc
larg in-lin expect highlight commerci
readi execut ayvakit initi launch prepar futur potenti ayvakit
indic expans initi launch ret inhibitor pralsetinib near-term pipelin
regulatori event remain track includ ayvakit phase voyag
readout gist potenti approv gist pdufa pralsetinib
complet roll nda submiss lung cancer expect regulatori file
medullari thyroid cancer maintain buy pt
commerci execut underway launch ayvakit initi indic
prepar multipl indic expans recal recent receiv
ahead-of-schedul approv ayvakit pdgfra gastrointestin stromal tumor link
consider line-up potenti expans opportun throughout
management note readi area busi manag in-plac incom
commerci pharmaci prescript first week post-approv
ayvakit track head remain pipelin regulatori mileston
phase voyag schedul read top-line data earli
enabl potenti avapritinib snda file regorafenib-na gist
supplement current file gist link pdufa separ updat
ism data present aaaai annual meet march abstract
releas week februari includ robust data includ patient-report
outcom safeti object measur respons inform registr part
studi reiter guidanc nda submiss advanc sm
ret inhibitor pralsetinib track complet roll nda ret nsclc
submit nda ret mtc recal compani recent read
updat ret nsclc data link centrally-assess contrast competitor
confirm among evalu mtc patient orr confirm
evalu mtc patient progress prior cabozantinib vandetanib
takeaway wherea recent read orr confirm among
patient progress prior tki orr confirm among tki-naiv
point differenti pralsetinib selpercatinib former higher
incid neutropenia vs latter liver enzym elev potenti impact
central vs local tumor assess readout differ complet respons rate
vs specif launch time
maintain guidanc early-stag asset phase initi
healthi volunt new develop candid recal
next-gener kit pdgfra inhibitor similar potenc ayvakit
without blood-brain barrier penetr potenti reduc toxic see
 day take-away preclinical-stag asset alreadi nomin inhibitor
osimertinib-resist egfr triple-mut nsclc may potenti
nomin addit asset recal day also highlight
immunokinas egfr double-mut inhibitor
updat estim account result follow-on offer
maintain buy pt end cash market
secur includ net proce januari follow-on offer
page analyst certif import disclosur
believ suffici fund oper point expect
gener meaning revenu maintain buy pt
page analyst certif import disclosur
valuat risk
valu per share use dcf base valuat method
valuat includ probability-adjust cash flow deriv compani pipelin
includ avapritinib use discount rate termin growth rate
appli termin year post-assum gener entri lead pipelin candid
risk valuat includ regulatori commerci setback
potenti emerg new competitor lower product sale expect
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
